title: Monitoring serum beta-2 microglobulin is useful for detecting patients with increased risk of acute rejection during reduction in immunosuppression.
authors.affiliation: Department of Medicine, Federal University of São Paulo, Brazil.
authors.forename: N O
authors.initials: NO
authors.lastname: Câmara
authors.forename: S
authors.initials: S
authors.lastname: Nishida
authors.forename: M S
authors.initials: MS
authors.lastname: Silva
authors.forename: J O
authors.initials: JO
authors.lastname: Pestana
authors.forename: A B
authors.initials: AB
authors.lastname: Pereira
authors.forename: R
authors.initials: R
authors.lastname: Sesso
authors.forename: A
authors.initials: A
authors.lastname: Pacheco-Silva
mesh_terms: D000208:Acute Disease; D000704:Analysis of Variance; D016001:Confidence Intervals; D003404:Creatinine / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006084:Graft Rejection / Q000097:blood / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008991:Monitoring, Physiologic; D016017:Odds Ratio; D012044:Regression Analysis; D018570:Risk Assessment; D012307:Risk Factors; D001613:beta 2-Microglobulin / Q000032:analysis*
chemical_list: D001613:beta 2-Microglobulin; D003404:Creatinine